Latest development4 months ago
Delta Air Lines Captures 50% of U.S. Airline Profits via Premium Strategy
Delta secures half of industry profits despite an 18% passenger share, driven by a 20% price premium for reliability.
Read the full story
Delta Air Lines and Bristol-Myers Squibb stocks are currently trading at discounts to their estimated fair values amid new operational catalysts. Bristol-Myers recently received EU approval for Opdivo, while Delta announced a $1 billion investment to retrofit its Airbus fleet starting in 2027. Despite carrying only 18% of passengers, Delta captures half of all U.S. airline profits, supported by customers paying a 20% premium for its reliable service.
Delta secures half of industry profits despite an 18% passenger share, driven by a 20% price premium for reliability.
Read the full storyThe U.S. carrier plans to retrofit 42 Airbus A330 aircraft starting in 2027, focusing on standardizing premium cabin experiences across its widebody fleet.
Delta Air Lines trades at a 22.9% discount to fair value, while Bristol-Myers Squibb secures key EU approval for its drug Opdivo.